Ardelyx (ARDX) Capital Expenditures (2013 - 2026)
Ardelyx's (ARDX) quarterly Capital Expenditures came in at $69000.0 in Q1 2026, down 78.77% YoY from $325000.0 in Q1 2025, and down 80.89% on a QoQ basis from $361000.0 in Q4 2025.
Ardelyx (ARDX) Capital Expenditures (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Capital Expenditures data on file, last reported at $69000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 78.77% year-over-year to $69000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 4.22% YoY) and the FY2025 annual result came in at $1.5 million, up 47.58% from the prior year.
- Capital Expenditures slipped to $69000.0 in Q1 2026, from $361000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $650000.0 in Q2 2025 to a low of $14000.0 in Q1 2023.
- A 5-year average of $212214.3 and a median of $143500.0 in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2024 — Capital Expenditures jumped 1279.07% — and 2026, when it slumped 78.77%.
- Tracing ARDX's Capital Expenditures over 5 years: stood at $55000.0 in 2022, then declined by 21.82% to $43000.0 in 2023, then jumped by 1279.07% to $593000.0 in 2024, then tumbled by 39.12% to $361000.0 in 2025, then plunged by 80.89% to $69000.0 in 2026.
- The last three Capital Expenditures figures came in at $69000.0 (Q1 2026), $361000.0 (Q4 2025), and $156000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 13,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13,000.00 |
| Jun 30, 2026 | 13,000.00 |
| Mar 31, 2026 | 69,000.00 |
| Mar 31, 2026 | 69,000.00 |
| Dec 31, 2025 | 361,000.00 |
| Dec 31, 2025 | 361,000.00 |
| Sep 30, 2025 | 156,000.00 |
| Sep 30, 2025 | 156,000.00 |
| Jun 30, 2025 | 650,000.00 |
| Jun 30, 2025 | 650,000.00 |
| Mar 31, 2025 | 325,000.00 |
| Mar 31, 2025 | 325,000.00 |
| Dec 31, 2024 | 593,000.00 |
| Dec 31, 2024 | 593,000.00 |
| Sep 30, 2024 | 137,000.00 |
| Sep 30, 2024 | 137,000.00 |
| Jun 30, 2024 | 131,000.00 |
| Jun 30, 2024 | 131,000.00 |
| Mar 31, 2024 | 150,000.00 |
| Mar 31, 2024 | 150,000.00 |